Repligen RGEN 深 沪
等待开盘 08-06 09:30:00 美东时间
115.89
-0.610
-0.52%
华盛通- 最 高117.7226
- 今 开116.64
- 成交量 56.14万股
- 最 低 115.04
- 昨 收 116.50
- 总市值 65.11亿
- 52周最高 182.52
- 市盈率 静 --
- 换手率 1.00%
- 52周最低 102.965
- 委 比 91.82%
- 总股本 5618.31万
- 历史最高 327.32
- 量 比 0.43
- 振 幅 2.30%
- 历史最低 2.90
- 每 手 1
- 风险率 23.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Repligen Stock Outlook: Risk Skewed To The Downside Through 2026
Repligen stock has been in a prolonged downtrend, and Adhishthana principles suggest more weakness ahead. Here's what investors should track...
07-31 22:45
Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization
Repligen Corporation and Novasign have formed a strategic partnership to integrate Novasign's machine learning and modeling workflows into Repligen's tangential flow filtration (TFF) systems. The collaboration aims to enhance Repligen's digitalization efforts, improve process analytical technology (PAT)-enabled systems, and enable real-time predictive control, reducing development timelines and costs through digital twins. Novasign's expertise in...
07-31 11:30
Wells Fargo Maintains Overweight on Repligen, Lowers Price Target to $175
Wells Fargo analyst Brandon Couillard maintains Repligen (NASDAQ:RGEN) with a Overweight and lowers the price target from $180 to $175.
07-30 22:11
Repligen Raises FY2025 Adj EPS Guidance from $1.63-$1.72 to $1.65-$1.72 vs $1.68 Est; Raises FY2025 Sales Guidance from $695.000M-$720.000M to $715.000M-$735.000M vs $709.438M Est
Repligen (NASDAQ:RGEN) raises FY2025 Adj EPS guidance from $1.63-$1.72 to $1.65-$1.72 vs $1.68 analyst estimate. Raises FY2025 sales outlook from $695.000 million-$720.000 million to $715.000 million-$735.000 million vs
07-29 19:33
Repligen Q2 Adj. EPS $0.37 Misses $0.39 Estimate, Sales $182.000M Beat $174.831M Estimate
Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.37 per share which missed the analyst consensus estimate of $0.39 by 5.85 percent. This is a 12.12 percent increase over earnings of $0.33 per share from the same
07-29 19:33
Earnings Scheduled For July 29, 2025
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is projected to repor...
07-29 16:32
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
Recursion announced it will host a quarterly earnings call on August 5, 2025, at 8:00 am ET, to discuss its second-quarter 2025 financial results and business updates. The event will stream live on X (Twitter), LinkedIn, and YouTube, with a Q&A session via a Google Form. Recursion, a clinical-stage TechBio company, uses its Recursion OS platform to decode biology and advance medicine. Investors can find more information on the company’s website o...
07-29 12:00
Forecasting The Future: 6 Analyst Projections For Repligen
6 analysts have expressed a variety of opinions on Repligen (NASDAQ:RGEN) over ...
07-23 03:00
Stephens & Co. Assumes Repligen at Overweight, Announces Price Target of $160
Stephens & Co. analyst Steven Etoch assumes Repligen (NASDAQ:RGEN) with a Overweight rating and announces Price Target of $160.
07-22 23:07
Repligen to Report Second Quarter 2025 Financial Results
Repligen Corporation will release its second quarter 2025 financial results on July 29, 2025, followed by a conference call and webcast at 8:30 a.m. ET. Domestic callers can join by dialing (800) 715-9871, while international callers can use (646) 307-1963. The webcast will be available via the company’s Investor Relations website. Both the call and webcast will be archived for future access. Jacob Johnson, VP, Investor Relations, is the contact ...
07-17 11:30
